Medical News

RSS

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Anesthesiologist group to-decertify physicians who help with lethal injections

The American Board of Anesthesiologists "has quietly decided to revoke the certification of any member who participates in executing a prisoner by lethal injection," according to The Washington Post. The decision "reflects its leaders' belief that 'we are healers, not executioners,' board secretary Mark A. Rockoff said. Although the American Medical Association has long opposed doctor involvement, the anesthesiologists' group is the first to say it will harshly penalize a health-care worker for abetting lethal injections.

3 May 2010

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Spectros announced today that it entered into a patent sale agreement with Koninklijke Philips Electronics N.V. ( PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.

3 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

AppDynamics closes Series B financing round, raises $11 million

AppDynamics, Inc.™, the next-generation Application Performance Management (APM) company, today announced that it has closed its Series B round of financing, and had raised $11 million. The round is co-led by existing Series A investors Lightspeed Venture Partners and Greylock Partners, and will support the company's continued expansion as it takes advantage of market demand for next-generation application performance management (APM). To date, the company has received $16.5 million in venture funding.

3 May 2010

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.

3 May 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals Co. today announced its financial results for the first quarter ended March 31, 2010. Compared with the first quarter of 2009, first quarter 2010 revenues increased sharply to $8.8 million, and operating expenses decreased by 20%. The Company had net income of $0.12 per share for the first quarter of 2010.

3 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Vascular Solutions acquires Escalon Medical's SMARTNEEDLE, pdACCESS businesses

Vascular Solutions, Inc. today announced that it has acquired the assets related to the SMARTNEEDLE™ and pdACCESS™ Doppler guided needle access business from Escalon Vascular Access, Inc., a division of Escalon Medical Corporation. The SMARTNEEDLE and pdACCESS products consist of a hand-held monitor and one-time use needles designed to provide auditory ultrasound guided access to arteries and veins during catheterization procedures.

3 May 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended March 31, 2010.

3 May 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International today announced first quarter financial results for 2010.

3 May 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

3 May 2010

SonoSite, Physio-Control announce development collaboration for point-of-care ultrasound in EMS market

SonoSite, Inc., the world leader and specialist in hand-carried ultrasound for the point-of-care, and Physio-Control, Inc., the global leader in the development and delivery of emergency medical response solutions, today announced a market development collaboration for point-of-care ultrasound in the emergency medical services (EMS) market. This alliance will enable SonoSite to expand its presence in the pre-hospital settings with the support of Physio-Control resources and extensive sales force.

3 May 2010

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Omeros Corporation today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits.

3 May 2010

Unisys sells HIM business to Molina Healthcare for $135 million

Unisys Corporation announced today that it has completed the previously announced sale of its health information management (HIM) business to Molina Healthcare, Inc. for $135 million in cash, subject to adjustment.

3 May 2010

Stealth interventions may help people eat better, exercise more: Study

How do you get college students to eat better? A new study from the Stanford University School of Medicine suggests that a "stealth" strategy of raising the students' awareness of environmental and social issues related to food can persuade them to eat more veggies and less ice cream.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

Investment report on Spectrum Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 May 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

Medical News

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Anesthesiologist group to-decertify physicians who help with lethal injections

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

AppDynamics closes Series B financing round, raises $11 million

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Vascular Solutions acquires Escalon Medical's SMARTNEEDLE, pdACCESS businesses

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

SonoSite, Physio-Control announce development collaboration for point-of-care ultrasound in EMS market

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Unisys sells HIM business to Molina Healthcare for $135 million

Stealth interventions may help people eat better, exercise more: Study

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Investment report on Spectrum Pharmaceuticals

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News